Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2015; 21(48): 13548-13554
Published online Dec 28, 2015. doi: 10.3748/wjg.v21.i48.13548
Published online Dec 28, 2015. doi: 10.3748/wjg.v21.i48.13548
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype
Yoshimasa Saito, Hiroshi Serizawa, Yukako Kato, Masaru Nakano, Division of Gastroenterology, Kitasato Institute Hospital, Minato-ku, Tokyo 108-8641, Japan
Yoshimasa Saito, Hidetsugu Saito, Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Minato-ku, Tokyo 105-8512, Japan
Yoshimasa Saito, Hidetsugu Saito, Hidekazu Suzuki, Takanori Kanai, Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan
Masahiko Nakamura, School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo 108-8641, Japan
Author contributions: Saito Y and Serizawa H designed the research; Saito Y, Serizawa H, Kato Y and Nakano M performed the clinical research; Nakamura M, Saito H, Suzuki H and Kanai T supervised the research; Saito Y and Serizawa H analyzed the data and wrote the paper.
Supported by Research Grant of Kitasato Institute Hospital.
Institutional review board statement: The study was reviewed and approved by the institutional review board of the Kitasato Institute Hospital.
Clinical trial registration statement: This study was registered with the UMIN Clinical Trials Registry, No. UMIN000009642.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None of the authors have any conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yoshimasa Saito, MD, PhD, Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. saito-ys@pha.keio.ac.jp
Telephone: +81-3-54002692 Fax: +81-3-54002692
Received: June 3, 2015
Peer-review started: June 3, 2015
First decision: August 26, 2015
Revised: September 3, 2015
Accepted: October 17, 2015
Article in press: October 20, 2015
Published online: December 28, 2015
Peer-review started: June 3, 2015
First decision: August 26, 2015
Revised: September 3, 2015
Accepted: October 17, 2015
Article in press: October 20, 2015
Published online: December 28, 2015
Core Tip
Core tip: Esomeprazole (EPZ) is considered to be more effective for inhibition of gastric acid secretion than other first-generation proton pump inhibitors (PPIs) because its metabolism is not influenced by CYP2C19 genotype. In the present study, however, first-line eradication by EPZ-based triple therapy for patients with Helicobacter pylori (H. pylori)-positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with triple therapies with other first-generation PPIs in the Japanese population. Unlike previous studies, our results suggest that there is no advantage for EPZ-based triple therapy on H. pylori eradication in comparison with other first-generation PPIs.